Prodrug


Prodrug

A prodrug is a pharmacological substance (drug) administered in an inactive (or significantly less active) form. Once administered, the prodrug is metabolised in vivo into an active metabolite, a process termed bioactivation. The rationale behind the use of a prodrug is generally for absorption, distribution, metabolism, and excretion (ADME) optimization. Prodrugs are usually designed to improve oral bioavailability, with poor absorption from the gastrointestinal tract usually being the limiting factor.

Additionally, the use of a prodrug strategy increases the selectivity of the drug for its intended target. An example of this can be seen in many chemotherapy treatments, in which the reduction of adverse effects is always of paramount importance. Drugs used to target hypoxic cancer cells, through the use of redox-activation, utilise the large quantities of reductase enzyme present in the hypoxic cell to bioactivate the drug into its cytotoxic form, essentially activating it. As the prodrug has low cytotoxicity prior to this activation, there is a markedly lower chance of it "attacking" healthy, non-cancerous cells which reduces the side-effects associated with these chemotherapeutic agents.

In rational drug design, the knowledge of both chemical properties likely to improve absorption and the major metabolic pathways in the body is used to modify the structure of new chemical entities for improved bioavailability. Conversely, the creation of prodrugs is sometimes unintentional, for example with serendipitous drug discoveries, where the drug is only later identified as a prodrug after extensive drug metabolism studies.

Contents

Classification

Prodrugs can be classified into two major types, based on their cellular sites of bioactivation into the final active drug form, with Type I being those that are bioactivated intracellularly (e.g., anti-viral nucleoside analogs, lipid-lowering statins,), and Type II being those that are bioactivated extracellularly, especially in digestive fluids or the systemic circulation (e.g., etoposide phosphate, valganciclovir, fosamprenavir, antibody-, gene- or virus-directed enzyme prodrugs [ADEP/GDEP/VDEP] for chemotherapy or immunotherapy). Both types can be further categorized into Subtypes, i.e. Type IA, IB and Type IIA, IIB, and IIC based on whether or not the intracellular bioactivating location is also the site of therapeutic action, or the bioactivation occurs in the gastrointestinal (GI) fluids or systemic circulation (see Table 1).

Type IA prodrugs include many antimicrobial and chemotherapy agents (e.g., 5-flurouracil). Type IB agents rely on metabolic enzymes, especially in hepatic cells, to bioactivate the prodrugs intracellularly to active drugs. Type II prodrugs are bioactivated extracelluarly, either in the milieu of GI fluids (Type IIA), within the systemic circulation and/or other extracellular fluid compartments (Type IIB), or near therapeutic target tissues/cells (Type IIC), relying on common enzymes such as esterases and phosphatases or target directed enzymes. Importantly, prodrugs can belong to multiple subtypes (i.e., Mixed-Type). A Mixed-Type prodrug is one that is bioactivated at multiple sites, either in parallel or sequential steps. For example, a prodrug, which is bioactivated concurrently in both target cells and metabolic tissues, could be designated as a “Type IA/IB” prodrug (e.g., HMG Co-A reductase inhibitors and some chemotherapy agents; note the symbol “ / ” applied here). When a prodrug is bioactivated sequentially, for example initially in GI fluids then systemically within the target cells, it is designated as a “Type IIA-IA” prodrug (e.g., tenofovir disoproxil fumarate; note the symbol “ - ” applied here). Many ADEPs, VDEPs, GDEPs and futuristic nanoparticle- or nanocarrier-linked drug moieties can understandably be Sequential Mixed-Type prodrugs. To differentiate these two Subtypes, the symbol dash “ - ” is used to designate and to indicate sequential steps of bioactivation, and is meant to distinguish from the symbol slash “ / ” used for the Parallel Mixed-Type prodrugs.[1][2]

Table 1: Classification of prodrugs
Type Bioactivation site Subtype Tissue location of bioactivation Examples
Type I Intracellular Type IA Therapeutic target tissues/cells Acyclovir, 5-Flurouracil, Cyclophosphamide, Diethylstilbestrol diphosphate,

L-Dopa, 6-Mercaptopurine, Mitomycin C, Zidovudine

Type I Intracellular Type IB Metabolic tissues (liver, GI mucosal cell,lung etc) Carbamazepine, Captopril, Carisoprodol, Heroin, Molsidomine, Paliperidone, Phenacetin, Primidone, Psilocybin, Suldinac, Tetrahydrofurfuryl disulfide
Type II Extracellular Type IIA GI fluids Lisdexamfetamine, Loperamide oxide, Oxyphenisatin, Sulfasalazine
Type II Extracellular Type IIB Systemic circulation and Other Extracellular Fluid Compartments Acetylsalicylate, Bacampicillin, Bambuterol, Chloramphenicol succinate,

Dihydropyridine pralixoxime, Dipivefrin, Fosphenytoin

Type II Extracellular Type IIC Therapeutic Target Tissues/Cells ADEPTs, GDEPs, VDEPs

Adapted from Pharmaceuticals (2:77-81, 2009) and Toxicology (236:1-6, 2007).

Examples

See also

References

  1. ^ see Table 1; Wu,K.M.: A New Classification of Prodrugs: Regulatory Perspectives Pharmaceuticals 2:77-81, 2009.<http://dx.doi.org/10.3390/ph2030077>.
  2. ^ see Table 1; Wu, K.M.; Farrelly, J.: Regulatory Perspectives of Type II Prodrug Development and Time-Dependent Toxicity Management: Nonclinical Pharm/Tox Analysis and the Role of Comparative Toxicology. Toxicology 2007, 236, 1–6. <http://dx.doi.org/10.1016/j.tox.2007.04.005>

External links


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Prodrug — Als Prodrug (das oder die Prodrug[1]) wird ein inaktiver oder wenig aktiver pharmakologischer Stoff bezeichnet, der erst durch Verstoffwechselung (Metabolisierung) im Organismus in einen aktiven Wirkstoff (Metaboliten) überführt wird. Prodrugs… …   Deutsch Wikipedia

  • prodrug — A class of drugs, the pharmacologic action of which results from conversion by metabolic processes within the body (biotransformation). * * * pro·drug prō .drəg n a pharmacologically inactive substance that is the modified form of a… …   Medical dictionary

  • prodrug — /proh drug /, n. Pharm. an inactive substance that is converted to a drug within the body by the action of enzymes or other chemicals. [PRO 1 + DRUG] * * * …   Universalium

  • prodrug — noun A drug that is administered in an inactive form that is metabolised in the body into a biologically active compound …   Wiktionary

  • Prodrug — Pro|drug 〈[ drʌg] f. 10; Pharm.〉 Arzneistoff, der als Vorstufe verabreicht u. im Organismus allmählich enzymatisch in einen Wirkstoff transformiert wird, Langzeitpräparat [<Pro... + engl. drug „Medikament, Droge“] * * * Pro|drug, Pro Drug [… …   Universal-Lexikon

  • Prodrug — Pro|drug 〈[ drʌg] f.; Gen.: , Pl.: s; Pharm.〉 Arzneistoff, der als Vorstufe verabreicht u. im Organismus allmählich enzymat. in einen Wirkstoff transformiert wird, Langzeitpräparat [Etym.: <Pro…+ engl. drug »Medikament, Droge«] …   Lexikalische Deutsches Wörterbuch

  • Prodrug — Pro|drug [ pro:drʌg] das od. die; [s], s <zu ↑pro... u. engl. drug »Droge, Arzneimittel«> Substanz, die selbst biologisch weitgehend inaktiv ist, aber im Organismus enzymatisch od. nicht enzymatisch in eine aktive Form umgewandelt wird (Med …   Das große Fremdwörterbuch

  • prodrug — noun a biologically inactive compound which can be metabolized in the body to produce a drug …   English new terms dictionary

  • prodrug — n. a drug that requires metabolism in the liver before becoming biologically active. Examples are carbimazole, which is metabolized to the pharmacologically active compound methimazole; and capecitabine, which is metabolized to fluorouracil …   The new mediacal dictionary

  • prodrug — pro•drug [[t]ˈproʊˌdrʌg[/t]] n. pha an inactive substance that is converted to a drug within the body by the action of enzymes or other chemicals …   From formal English to slang


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.